Supplemental material
Expert Review of Anti-infective Therapy
Volume 15, 2017 - Issue 5
Original Research
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis
, , , , 
, , , & show all
Sven Van PouckeDepartment of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Ziekenhuis Oost-Limburg, Genk, Belgiumhttp://orcid.org/0000-0001-8070-8786View further author information
http://orcid.org/0000-0001-8070-8786View further author information, , , & Ming-Hua ZhengDepartment of Hepatology, Liver Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;Institute of Hepatology, Wenzhou Medical University, Wenzhou, ChinaCorrespondence[email protected]
http://orcid.org/0000-0003-4984-2631View further author information
http://orcid.org/0000-0003-4984-2631View further author information show allReprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma.
Source:
Springer Science and Business Media LLC
Lamivudine in HBV Carriers with Lymphoma
Source:
Wiley
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
Source:
Wiley
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis
Source:
Taylor & Francis
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection
Source:
Elsevier BV
A Randomized Clinical Trial
Source:
American Medical Association (AMA)
HBV reactivation in cancer patients
Source:
Wiley
Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients
Source:
Springer Science and Business Media LLC
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
Source:
European Association for the Study of the Liver. Published by Elsevier Ireland Ltd.
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
Source:
Elsevier BV
Allogeneic Hematopoetic Cell Transplantation In Patients Positive For Hepatitis B Surface Antigen
Source:
American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.
The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
Source:
Korean Academy of Medical Sciences
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.
Source:
American Society of Hematology
Preventing hepatitis B reactivation
Source:
Wiley
The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy
Source:
Springer Science and Business Media LLC
Linking provided by
